Latest Regulatory News

New Hope has agreed to acquire the Malabar shares it does not already own in an all-scrip deal valuing Malabar at about A$1.8 billion. The transaction would give New Hope full control of the ramping Maxwell underground mine and create a coal group targeting roughly 19Mtpa of saleable production.

Ampol's third-quarter trading strengthened as Lytton refinery margins more than doubled and Convenience Retail sales surged, but extra maintenance will reduce expected fourth-quarter higher-value product output by about 150 million litres. The Ultra Low Sulfur Fuels project has also slipped into the first quarter of 2027, while the proposed Evie Networks acquisition awaits regulatory clearance.

Reliance Worldwide Corporation’s go-shop period has ended without an alternative proposal, leaving Brookfield’s US$3.38-per-share takeover as the only deal before shareholders. The board has reaffirmed its unanimous recommendation, but the scheme still requires shareholder, Court, regulatory and expert approval.

Buru Energy has applied for a Production Licence covering its wholly owned Rafael gas and condensate field in Western Australia, moving the project into another key regulatory phase. The application follows the booking of 15.25 MMboe of 2P Reserves and keeps planned 2027 drilling and early 2029 first gas in view, subject to approvals and funding.

Bendigo Bank’s unaudited 1Q27 cash earnings rose 18.5% against the prior half-year quarterly average, but statutory profit fell as net interest margin narrowed and non-cash property revaluations weighed. Deposits grew while lending contracted, with the bank continuing its costly non-financial risk remediation program.

TAL Daiichi Life Australia has tabled a conditional $11.80-per-share proposal to acquire the 79.5% of Challenger it does not already own. The approach arrives as Challenger reports a 52% jump in first-quarter sales, but remains non-binding and subject to due diligence, regulatory approval and a board recommendation.

Ramsay Health Care has cleared the first legal step towards distributing its 52.79% stake in Ramsay Générale de Santé to shareholders. The proposed demerger now goes to consecutive shareholder meetings on 24 November, backed by the board and Deloitte’s independent expert.

Bounty Oil & Gas reported a larger FY2026 loss and weaker production, while reshaping its portfolio around Queensland oil development and a proposed deepwater Liberia entry. The strategy is backed by fresh equity, but depends on further funding, regulatory progress and a production sharing contract that has not yet been finalised.

Aeris Resources finished FY26 with $178.5 million in net profit, $290.2 million of EBITDA and no material debt, while Tritton’s copper reserves expanded sharply. The challenge now shifts from rebuilding the balance sheet to converting a larger resource base into sustained production.

Amplia Therapeutics has told ASX it is unaware of any undisclosed information that explains a sharp fall in its share price and a surge in trading volume. The response followed an ASX price query issued after the stock dropped from $0.100 to $0.079 on 16 October.

Minerals Exploration has expanded its New Zealand exploration pipeline after broad gold intersections at Jubilee South and high-grade tungsten results at Invincible. The next phase is more ambitious, but A$1.96 million in cash covers only 1.91 quarters at the latest spending rate.

Noxopharm has completed its first-in-human safety trial for SOF-SKN and advanced the wider Sofra platform, but its annual report flags a material uncertainty over funding. The biotech ended June with A$293,573 in cash, net liabilities of A$3.65 million and a need for additional capital.